Balyasny Asset Management
IMDZ

Balyasny Asset Management’s Immune Design Corp. IMDZ Stock Holding History

Balyasny Asset Management’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-24,712
Closed -$112K – 2289
2018
Q2 		$112K Sell
24,712
-36,100
-59% -$144K ﹤0.01% 1703
2018
Q1 		$201K Buy
60,812
+11,800
+24% +$41.8K ﹤0.01% 1766
2017
Q4 		$191K Buy
49,012
+38,475
+365% +$210K ﹤0.01% 1919
2017
Q3 		$109K Buy
+10,537
New +$104K ﹤0.01% 1769

Other funds holding IMDZ

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's IMDZ Position: Q3 2018 in Review

Balyasny Asset Management sold out of Immune Design Corp. (IMDZ) in Q3 2018, closing a stake of 24,712 shares — an estimated $112K sold.

Balyasny Asset Management first reported a position in IMDZ in Q3 2017 and held it in 4 quarters. The position peaked at $201K in Q1 2018. 71 funds tracked by Wall St. Rank hold IMDZ as of Q3 2018.

  • Balyasny Asset Management reported no remaining Immune Design Corp. position as of Q3 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 24,712 Immune Design Corp. shares in Q3 2018, an estimated $112K.
  • Balyasny Asset Management first reported a position in Immune Design Corp. in Q3 2017 and held it in 4 quarters.
  • Balyasny Asset Management's Immune Design Corp. position peaked at $201K in Q1 2018.
  • 71 funds tracked by Wall St. Rank held Immune Design Corp. as of Q3 2018.

Based on Balyasny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.